EAACI Congress 2024
BackTPS13 - Allergen immunotherapy 2
Friday 31 May, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
Analytical testing of PQ Grass allergoid drug product using antibodies
Assessing specific pro-catabolic mediators (SPMs) as Innovative Biomarkers in Allergen Immunotherapy: Monitoring Treatment Efficacy
Can serum biomarkers predict long-term control of allergic rhinitis after immunotherapy?
Clinical evaluation of an immunotherapy treatment with Vespa velutina venom in allergic patients. Results from a prospective multicenter Study: W-STING Study
Early inflammatory reactions in mice after immunotherapy with an allergen microcrystalline tyrosine adsorbate
First-in-class biologic to treat House dust mite allergy
In vitro safety profile and tolerogenic response with depigmented and polymerized extracts in polyallergic patients to grass pollen and cat epithelia
Interim safety review of PVX108 peptide immunotherapy in an ongoing Phase 2 trial in peanut-allergic adolescents and children
Intravenous immunotherapy with Der p 1-containing nanoparticles alleviates allergic response in a murine model of allergic rhinitis
Missense variant KIT p.D816V suggestive of mast cell disorder predisposes to Hymenoptera venom immunotherapy treatment complications and failure
Safety and tolerance response of a two day rush protocol treatment in immunotherapy using purified Apis mellifera dry Honeybee venom extract
Subcutaneous allergen-specific immunotherapy- Safety and risk factors of adverse effects. Data from a tertiary allergy centre
The importance of detecting co-sensitization in patients with seasonal allergic rhinitis
The utility of basophil activation testing in honey bee venom allergy diagnosis and venom immunotherapy
Сytokine profiles in patients with allergic rhinitis during allergen-specific immunotherapy with and without added vitamin D
